Obsidio™ Conformable Embolic Registry

CompletedOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

September 9, 2025

Study Completion Date

September 9, 2025

Conditions
Hypervascular TumorsBleedingHemorrhage
Interventions
DEVICE

Obsidio™ Conformable Embolic

Embolization with Obsidio™ Conformable Embolic.

Trial Locations (20)

10029

Mount Sinai Medical Center, New York

12208

Albany Medical Center, Albany

19718

Christiana Hospital, Newark

20007

MedStar Georgetown University Hospital, Washington D.C.

27599

University of North Carolina Hospital, Chapel Hill

30322

Emory University Hospital, Atlanta

55433

Mercy Hospital, Coon Rapids

60611

Northwestern Memorial Hospital, Chicago

60637

University of Chicago Hospital, Chicago

63110

Barnes Jewish Hosital, St Louis

66160

University of Kansas Hospital, Kansas City

77030

The University of Texas MD Anderson Cancer Center, Houston

University of Texas Houston Health Science Center, Houston

85054

Mayo Clinic Hospital, Phoenix

90095

Ronald Reagan UCLA Medical Center, Los Angeles

95204

St. Joseph's Medical Center, Stockton

98195

University of Washington Medical Center, Seattle

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

07103

University Hospital, Newark

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY